Article citationsMore>>

Ferris, S., Nordberg, A., Soininen, H., Darreh-Shori, T. and Lane, R. (2009) Progression from Mild Cognitive Impairment to Alzheimer’s Disease: Effects of Sex, Butyrylcholinesterase Genotype, and Rivastigmine Treatment. Pharmacogenetics and Genomics, 19, 635-646.
http://dx.doi.org/10.1097/FPC.0b013e32832f8c17

has been cited by the following article:

• TITLE: Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia

  AUTHORS: Beate Mueller, Georg Adler

  KEYWORDS: Butyrylcholinesterase, Alzheimer’s Disease, Genotype

  JOURNAL NAME: World Journal of Neuroscience, Vol.5 No.3, June 2, 2015

  ABSTRACT: Approximately, two-thirds patients with Alzheimer’s disease (AD) are reported to have homozygous wild-type butyrylcholinesterase (BuChE) gene expression. It is associated with a higher rate of hydrolysis of acetylcholine, which ultimately leads to increase in the levels of BuChE in advanced stages of the disease. Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and BuChE, might be of additional benefit in patients with AD with wild-type BuChE allele.